Table of contents
December 2005 Volume 2 No 12
Editorial
Viewpoints
Should combination therapy be standard for benign prostatic hyperplasia?
574For patients with benign prostatic hyperplasia, pharmacologic treatment has emerged as an attractive alternative to surgical intervention; however, there are unresolved questions regarding nonsurgical approaches. The author reviews the evidence to address one such question: whether a combination of two drugs provides greater symptomatic relief than standard monotherapy.
The International Continence Society terminology for the lower urinary tract: the importance of standardization
576Over the years, the International Continence Society (ICS) has produced a series of standardization reports concerning the terminology of lower urinary tract function. In this Viewpoint, the authors highlight the advantages of using standardized ICS terminology in both clinical and scientific practice.
Research Highlights
Postoperative prognostic prediction models for nonmetastatic RCC
578Tumor multifocality is associated with worse outcome in prostate cancer
578Predicting mortality after hormonal therapy for postsurgical or postradiologic PSA failure
579Use of 
-blocker therapy for dysfunctional voiding in children
579Noninvasive measurement of bladder obstruction in men
580Improved clinical outcome in prostate cancer: real or statistical artefact?
580A third of phase I oncology trials remain unreported
580Enuresis alarm alone as effective as alarm with drugs
582Efficacy of prophylactic levofloxacin in cancer patients with neutropenia
582Practice Points
Can we preoperatively identify men who are at high risk for aggressive prostate cancer?
584Is carboplatin as effective as radiotherapy for the adjuvant treatment of stage I seminoma?
586Does lymphadenectomy improve cancer-specific survival in patients with renal cell carcinoma?
588High-dose chemotherapy in germ-cell cancer salvage regimens: where next?
590What are the survival outcomes for prostate cancer in a population-based cohort of unscreened men?
592Reviews
Angiogenesis imaging in the management of prostate cancer
596The process of angiogenesis is central to the development and spread of cancer. Modern imaging techniques are increasingly offering ways in which the markers of angiogenesis can be visualized. This article discusses the different imaging methods that can be used to assess angiogenesis in the prostate gland.
doi:10.1038/ncpuro0356 | Full Text | PDF (1,123K)
Therapy Insight: osteoporosis during hormone therapy for prostate cancer
608Gonadotropin-releasing hormone (GnRH) agonists are commonly used to treat men with prostate cancer. The hypogonadal state induced by GnRH agonists can lead to increased bone loss and, ultimately, osteoporosis in many men. This review outlines the mechanisms involved in bone loss associated with GnRH agonists and discusses the different measures that can be utilized in the treatment and prevention of osteoporosis in this group of patients.
doi:10.1038/ncpuro0326 | Full Text | PDF (133K)
Mechanisms of Disease: normal and abnormal gonadal development and sex determination in mammals
616In order to understand the mechanisms behind abnormal gonadal development it is important to understand the process of normal development. In this review, the normal development of the gonad in mammals, and the molecular pathways and candidate genes that have been implicated in abnormal gonadal development, are discussed.
doi:10.1038/ncpuro0354 | Full Text | PDF (212K)
